Skip to content

Prospective Registration and Assessment of Serious Adverse Events Within the AFNET

Prospective Registration and Independent Assessment of Incidence, Clinical Relevance and Outcome of Serious Adverse Events (SAE) Registered in the German Competence Network on Atrial Fibrillation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01678456
Acronym
AFNET A7
Enrollment
13000
Registered
2012-09-05
Start date
2004-02-29
Completion date
2012-12-31
Last updated
2020-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessment by a Critical Event Committee, Assessment of Serious Advers Events, Atrial Fibrillation, Complications of Antiarrhythmic Drugs or Invasive Procedures, Thromboembolic and Bleeding Complications

Keywords

Atrial Fibrillation, Critical Event Committee, Serious adverse events, Thromboembolic complications, Cardiac and noncardiac complications, Bleeding complications, Acute heart failure, Syncope, Resuscitation

Brief summary

Prospective registration and independent assessment of SAE associated with atrial fibrillation such as thromboembolic events, and other cardiac and noncardiac complications by a Critical Event Committee.

Detailed description

Atrial fibrillation (AF), the most common sustained rhythm disturbance, is associated with a significantly enhanced mortality and morbidity due to thromboembolic events, and other cardiac and noncardiac complications. Therefore the Network of Competence on Atrial Fibrillation (AFNET) supported by the German Ministry for Education and Research (BMBF) was established in order to collect clinical data on patients (pts) with AF (paroxysmal, persistent, permanent) over a study period of 6 years with an expected sample size of 12,000 pts. Incidence, clinical relevance and outcome after SAE is recorded and assessed by a Critical Event Committee (CEC). The CEC-members (experts in cardiology and neurology) defined as SAE any death with or without relationship to AF, cardio-embolic events (stroke, peripheral arterial embolism), bleeding complications due to antithrombotic therapy, acute heart failure, syncope, resuscitation; additionally, the complication of interventional strategies for AF-treatment and other AF-independent SAEs. Over a 3-year follow-up period, during 6-monthly and unscheduled visits, the SAEs are systematically documented, blinded and their relationship to AF will be interpreted in detail by the CEC.

Interventions

None listed

Sponsors

Atrial Fibrillation Network
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Atrial fibrillation documented by ECG not older then one year * Age \> 18 years * Informed consent

Exclusion criteria

* none

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026